Combined Technique for the Application of Micropulse Cyclophotocoagulation in Patients with Uncontrolled Glaucoma: Cyclo Mix.
Cyclodestruction
Glaucoma
Intraocular pressure
Micropulse laser
Transscleral cyclophotocoagulation
Journal
Journal of current glaucoma practice
ISSN: 0974-0333
Titre abrégé: J Curr Glaucoma Pract
Pays: India
ID NLM: 101492611
Informations de publication
Date de publication:
Historique:
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
20
4
2021
Statut:
ppublish
Résumé
To describe the outcomes of a combined technique (Cyclo Mix) in uncontrolled glaucoma cases. Retrospective study. The Supra 810 nm subliminal laser (Quantel Medical, Cournon d'Auvergne, France) was used. A combined technique was performed using the subliminal mode (Subcyclo) in one hemifield (power of 2,000 mW, a duty cycle of 35%, and 80-150 seconds), and the continuous wave mode (Thermo Cyclo) on the other hemifield (power of 1,000 mW, exposure time of 2 seconds per spot). The primary endpoint was the probability of surgical failure. Mean intraocular pressure (IOP) change, best-corrected visual acuity (BCVA), number of glaucoma eye drops, and complications at 6 months postoperatively were secondary outcomes. Twenty-three eyes from 13 patients were included. Mean age was 61.4 ± 16.7 (range: 18-78 years), and 69% were female, with a baseline IOP of 20.3 ± 5.9 (range: 13-38 mm Hg). The cumulative probability of failure was 18 and 22% on days 90 and 180, respectively. Mean IOP reduction was -25.6 ± 20.9% at 6 months. The number of glaucoma eye drops was reduced to 1.2 ± 1 ( Cyclo Mix seems to be a safe therapy that effectively reduces the IOP and glaucoma medications in eyes with uncontrolled open-angle glaucoma for up to 6 months. Waldo L-G, Julio H-Q, Jennifer C-V,
Identifiants
pubmed: 33867757
doi: 10.5005/jp-journals-10078-1289
pmc: PMC8028033
doi:
Types de publication
Journal Article
Langues
eng
Pagination
93-97Informations de copyright
Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.
Déclaration de conflit d'intérêts
Source of support: Nil Conflict of interest: None
Références
Am J Ophthalmol. 1992 Jan 15;113(1):81-5
pubmed: 1728152
Clin Exp Ophthalmol. 2015 Jan-Feb;43(1):40-6
pubmed: 24811050
Surv Ophthalmol. 2019 Jul - Aug;64(4):486-497
pubmed: 30639207
Arch Ophthalmol. 2003 Jan;121(1):48-56
pubmed: 12523884
J Glaucoma. 2017 Aug;26(8):726-729
pubmed: 28671927
Clin Exp Ophthalmol. 2010 Apr;38(3):266-72
pubmed: 20447122
Lancet. 2004 May 22;363(9422):1711-20
pubmed: 15158634
Eye (Lond). 2007 Jul;21(7):936-40
pubmed: 16628239
J Glaucoma. 2019 Mar;28(3):270-275
pubmed: 30601220
Am J Ophthalmol. 2000 Oct;130(4):429-40
pubmed: 11024415
J Glaucoma. 2020 Apr;29(4):264-270
pubmed: 31972595
J Glaucoma. 2018 Oct;27(10):874-879
pubmed: 30113509
J Glaucoma. 2020 Feb;29(2):97-103
pubmed: 31764578
Ophthalmology. 1990 Jan;97(1):69-72
pubmed: 2179798
J Glaucoma. 2018 May;27(5):445-449
pubmed: 29521718
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815